Hormonal
Semaglutide significantly reduces the risk of acute myocardial infarction and angina pectoris in patients with overweight or obesity, with greater efficacy observed in patients over 60 years and those treated for more than 52 weeks.
For patients with overweight or obesity, semaglutide (up to 2.4 mg) significantly lowers the risk of heart attacks and angina. This benefit is particularly pronounced in patients over 60 years old and those who maintain treatment for more than one year, suggesting that long-term adherence is key to maximizing cardiovascular protection.
semaglutide significantly reduced the risk of acute myocardial infarction (RR 0.72, 95% CI 0.60–0.85), and angina pectoris (RR 0.77, 95% CI 0.61–0.98)... Subgroup analyses revealed greater efficacy in patients over 60 years old and those treated for more than 52 weeks
Why this rating
Meta-analysis of 10 RCTs; low heterogeneity for AMI and angina.
Source
Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis
Rui Wu et al. · European journal of medical research · 2025
DOI 10.1186/s40001-025-03124-y
More from this paper
- Semaglutide significantly reduces the risk of atrial fibrillation (AF) and sinus node dysfunction in patients with overweight or obesity.Good
- Semaglutide does not significantly impact renal outcomes, including nephrolithiasis, acute kidney injury, or chronic kidney disease, in patients with overweight or obesity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →